138108-43-7

Basic information

• Product Name: L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-L-a-aspartyl-, bis(phenylmethyl) ester
• CAS NO: 138108-43-7
• Molecular Formula: C32H36N2O7
• Molecular Weight: 560.647
• Mol File: 138108-43-7.mol
• Article Data: 15

Chemical Properties

• CAS DataBase Reference: L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-L-a-aspartyl-, bis(phenylmethyl) ester(CAS DataBase Reference)
• NIST Chemistry Reference: L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-L-a-aspartyl-, bis(phenylmethyl) ester(138108-43-7)
• EPA Substance Registry System: L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-L-a-aspartyl-, bis(phenylmethyl) ester(138108-43-7)

Safety Data

• Hazardous Substances Data: 138108-43-7(Hazardous Substances Data)

Upstream product

• 7536-58-5 BOC-L-aspartic acid 4-benzyl ester 
• 84308-16-7 (S)-phenylalanine benzyl ester benzene sulfonate 
• 1738-78-9 L-phenylalanine benzyl ester p-toluene-sulfonic acid salt 
• 2462-32-0 L-phenylalanine benzyl ester hydrochloride 
• 962-39-0 L-Phenylalanine benzyl ester 
• 118517-08-1 (S)-3-tert-Butoxycarbonylamino-4-isopropoxycarbonyloxy-4-oxo-butyric acid benzyl ester 

Downstream Products

• 138108-45-9 N-<3-(benzyloxycarbonyl)-N-<5-benzamido>valeryl>-L-alanyl>-3-phenyl-L-alanine benzyl ester 
• 1025838-55-4 (S)-N-((S)-1-Benzyloxycarbonyl-2-phenyl-ethyl)-3-[5-(4-carbamimidoyl-benzoylamino)-pentanoylamino]-succinamic acid benzyl ester 
• 138108-44-8 N-<3-<(benzyloxy)carbonyl>-N-<5-(1-tert-butoxyformamido)valeryl>-L-alanyl>-3-phenyl-L-alanine benzyl ester 
• 1026442-85-2 4-[3-({[(S)-2-Benzyloxycarbonyl-1-((S)-1-benzyloxycarbonyl-2-phenyl-ethylcarbamoyl)-ethylcarbamoyl]-methyl}-ethyl-carbamoyl)-propyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 801317-53-3 4-oxo-4-(4-Boc-piperazin-1-yl)butyryl-glycyl-L-aspartyl-L-phenylalanine 
• 945469-80-7 C₅₂H₅₁N₇O₁₁S 
• 945469-79-4 C₅₁H₄₉N₇O₁₁S 
• 945469-78-3 C₅₄H₅₁N₅O₇S 
• 945469-77-2 C₃₉H₄₃N₅O₉S 

Relevant articles and documents

Preparation and application of polyaspartyl - RGDF - anti-tumor drug complex

The invention discloses a polyasparagine-RGDF compound represented by the formula and a three dimensional morphology of the compound under a neutral condition or a condition of pH 5.4, a polyasparagine-RGDF-antitumor drug compound, wherein the mole ratio

Thrombus targeting release of the antithrombotic RGDF [...] - RGDF synthesis and application of

The invention relates to polyaspartoyl-RGDF capable of achieving RGDF targeting release in thrombus, relates to a preparation method of the polyaspartoyl-RGDF, relates to the targeting antithrombotic function of the polyaspartoyl-RGDF on a rat thrombus mo

NOVEL COMPOUND WITH EFFECTS OF THROMBOLYSIS, FREE RADICAL SCAVENGING AND THROMBUS-TARGETING AS WELL AS PREPARATION METHOD AND USE THEREOF

The present invention discloses a novel compound with effects of thrombolysis, free radical scavenging and thrombus-targeting, as well as a preparation method and use thereof. The compound is a ternary conjugate formed by conjugating a thrombolytic peptide, a free radical scavenger and a thrombus-targeting/antithrombotic peptide together via a linking arm. The present invention also discloses a pharmaceutical composition containing the compounds, wherein the compounds form a nanospherical structure.